IVIG (intravenous immunoglobulin) is one of the most expensive recurring treatments in the U.S., with total costs often ranging from $5,000 to $10,000 or more per infusion before insurance. Even with good coverage, most patients face significant out-of-pocket expenses because of how the drug is priced and billed. Your actual cost depends on your insurance type, where you receive the infusion, and whether you qualify for financial assistance programs.
What IVIG Costs Before Insurance
IVIG is priced per gram, and the dose is based on your body weight. A standard dose for many conditions is 2 grams per kilogram of body weight, spread across multiple infusions. For a 155-pound (70 kg) person, that works out to about 140 grams of medication per treatment course. At current prices, which have climbed well above $100 per gram for many brand-name products, a single course can easily reach $10,000 to $30,000 depending on the brand and setting. Patients with chronic conditions like primary immunodeficiency or CIDP (chronic inflammatory demyelinating polyneuropathy) typically need infusions every 3 to 4 weeks, which means annual costs can land anywhere from $30,000 to over $150,000.
The medication itself accounts for the bulk of the bill, but it’s not the only charge. Facilities also bill for nursing time, IV supplies, premedications (like antihistamines or anti-nausea drugs given before the infusion), and monitoring. These add hundreds to thousands of dollars per session depending on the location.
How Insurance Typically Covers IVIG
Most private insurance plans cover IVIG under the medical benefit rather than the pharmacy benefit, which means it’s billed like a procedure rather than a prescription. This distinction matters because medical benefit cost-sharing usually involves coinsurance (a percentage of the total cost) rather than a flat copay. If your plan has 20% coinsurance, a $10,000 infusion leaves you with a $2,000 bill for that single session.
Some insurers are shifting IVIG to the pharmacy benefit through specialty channel management programs. This can sometimes lower the plan’s cost, but it may increase yours. Pharmacy benefits often come with higher copays or coinsurance tiers for specialty drugs. When your insurer makes this switch, it’s worth comparing what your out-of-pocket share looks like under each benefit structure.
Nearly all insurers require prior authorization before approving IVIG. You’ll need documentation from your doctor showing a confirmed diagnosis for an approved condition, evidence that other treatments haven’t worked or aren’t appropriate, and sometimes lab results supporting the need. Approval is typically granted for a set number of infusions, after which your doctor must resubmit for continued coverage. Denials aren’t uncommon, especially for conditions where IVIG is used off-label, and appeals can take weeks.
What You’ll Pay Out of Pocket
Your actual cost depends on three things: your deductible, your coinsurance rate, and your plan’s out-of-pocket maximum. Because IVIG is so expensive, most patients hit their annual out-of-pocket maximum early in the year. For 2025, the Affordable Care Act caps out-of-pocket maximums at $9,200 for individual marketplace plans and $18,400 for family plans, though many employer-sponsored plans set lower limits.
In practical terms, this means you’ll likely pay your full deductible with your first infusion or two, then coinsurance on subsequent infusions until you reach your out-of-pocket cap. After that, your plan covers 100% for the rest of the year. For someone with a $3,000 deductible and 20% coinsurance on a plan with a $7,500 out-of-pocket max, the first few months of IVIG could cost $7,500 total before the cap kicks in. That resets every January.
Medicare Coverage
Medicare Part B covers IVIG for certain conditions, particularly primary immunodeficiency. For 2025, Medicare’s payment rate for IVIG administered in the home is $431.83 per infusion day, with a slight increase to $442.19 for 2026. Patients on original Medicare are responsible for 20% coinsurance after meeting the Part B deductible. If you have a Medigap supplement, it may cover some or all of that 20%. Medicare Advantage plans vary, so check your specific plan’s specialty drug and infusion coverage.
Where You Get Infused Changes the Price
The setting where you receive IVIG has a dramatic effect on the total bill, and by extension, on your coinsurance. Hospital outpatient departments are consistently the most expensive option. A large claims analysis covering nearly 43 million commercially insured people found that the cost per infusion was 31% lower in the home setting compared to hospital outpatient departments: $3,293 at home versus $4,745 in the hospital. Another study found that patients who switched from hospital outpatient infusions to home infusions saw their median costs drop from $6,916 to $4,188 per infusion.
Independent infusion clinics and doctor’s offices typically fall between hospital and home pricing. They bill based on the drug cost plus an administrative fee, which is generally lower than the facility fees hospitals charge. Home infusion adds costs for a visiting nurse and equipment, but even with those charges, it’s usually the least expensive option for both the insurer and the patient. If your plan’s coinsurance is percentage-based, a lower total cost directly reduces what you owe. Ask your doctor and insurer whether home infusion is an option for your condition.
Financial Assistance Programs
Because out-of-pocket costs for IVIG can reach thousands of dollars annually even with insurance, several types of assistance programs exist to help close the gap.
Most major IVIG manufacturers offer copay assistance programs for commercially insured patients. These programs reduce or eliminate your coinsurance and copays, sometimes covering up to the full out-of-pocket cost. Brands with active programs include Gamunex-C (Grifols), Gammagard Liquid (Takeda), Privigen (CSL Behring), Octagam and Panzyga (Octapharma), Bivigam and Asceniv (ADMA Biologics), and Gammaplex and Gammaked (Kedrion). Each program has its own annual caps and eligibility rules. Your infusion provider or specialty pharmacy can usually help you enroll, or you can contact the manufacturer directly. These programs generally do not cover patients on Medicare or Medicaid.
For patients on government insurance or those who don’t qualify for manufacturer programs, nonprofit foundations can help. The Assistance Fund (TAF) covers copays and out-of-pocket costs for patients with primary immunodeficiency, chronic granulomatous disease, and other qualifying conditions. Eligibility is based on household size and income. The PAN Foundation offers grants for copays, insurance premiums, and even transportation costs, though its programs are organized by disease category and may cover IVIG-related conditions like autoimmune disorders rather than immunodeficiency directly. The Immune Deficiency Foundation maintains an updated list of all available programs on its website.
Steps to Lower Your Costs
- Request home or clinic infusion. Moving out of the hospital outpatient setting can cut per-infusion costs by 30% or more, directly reducing your coinsurance.
- Enroll in a copay program early. Manufacturer assistance programs are available year-round but have annual caps. Enrolling before your first infusion of the year maximizes the benefit.
- Track your out-of-pocket maximum. Because IVIG is so costly, you’ll likely hit your annual cap within a few months. Scheduling other medical procedures or tests during this “free” window can save money on unrelated care.
- Ask about product switching. Different IVIG brands have different prices, and your insurer may have a preferred product that costs less under your plan. Your doctor can determine whether switching brands is medically appropriate.
- Appeal denials promptly. If your insurer denies coverage or limits the number of approved infusions, you have the right to appeal. Your doctor’s office can provide supporting documentation, and patient advocacy organizations like the Immune Deficiency Foundation offer guidance on navigating the appeals process.